Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-3750 in mild to moderate COPD
NCT07076290Phase 1Not yet recruiting
- Sponsor
- Rise Therapeutics
- Start
- Sep 2026
- Primary completion
- Apr 2028
- Modality
- Live Biotherapeutic Products
01
Overview
Phase 1, open-label, single-arm trial of R-3750 in chronic obstructive pulmonary disease (COPD), sponsored by Rise Therapeutics. Primary endpoint: Treatment-related adverse events at 12 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
R-3750
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07076290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07076290.